The Potential of High-Density Lipoprotein as a Predictive Biomarker for Infliximab Efficacy in Crohn’s Disease
Keke Tang, Ziheng Peng, Duo Xu, Yong Li, Xiaowei Liu, Guanghui Lian, Yu Peng · 2025
Read The Potential of High-Density Lipoprotein as a Predictive Biomarker for Infliximab Efficacy in Crohn’s Disease by Keke Tang, Ziheng Peng, Duo Xu, Yong Li, Xiaowei Liu, Guanghui Lian, Yu Peng (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751287.txt.
Description
Keke Tang and co-authors present a 2025 study that tests whether a blood fat marker can predict how Crohn's disease patients fare on a common drug. They reviewed past care at one Chinese hospital for patients on infliximab. Poor outcomes meant active disease, a change of care, surgery, or an unplanned return within a year.
About a fifth of patients met a poor outcome. Those with higher levels of the marker, known as HDL, did better on the whole. High HDL went with better nutrition and lower body swelling. Low HDL stood out on its own as a risk flag. The authors propose a simple blood test could help flag patients who need closer watch.
Catalog record
| CREATOR | Keke Tang, Ziheng Peng, Duo Xu, Yong Li, Xiaowei Liu, Guanghui Lian, Yu Peng |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 33 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |